DCDC Tx founded Metamorphosis Tx to develop cancer differentiation therapy

December 2023.

December 20, 2023. Metamorphosis Tx has been founded as a subsidiary of DCDC Tx. BioDetection Systems (BDS) is co-founder of Metamorphosis. Metamorphosis is dedicated to development of cancer differentiation therapy. DCDC Tx and BioDetection Systems make their proprietary technologies available to Metamorphosis. The proprietary CALUX reporter cell line technology of BDS complements the STAP-STP technology of DCDC-Tx. Combined use of STAP and CALUX  Signal Transduction Pathway technologies enables Metamorphosis to develop cancer differentiation therapies using both existing drugs (drug repurposing) and new drug discovery. Initial focus is on highly malignant glioblastoma multiforme (GBM) and pediatric DIPG (diffuse Intrinsic Pontine Glioma), ovarian cancer and aggressive types of breast cancer.

DCDC Tx receives two grants in academic collaborations to develop therapy for Post-COVID

February 2024: Preclinical and early clinical drug repurposing therapy development based on biological rationale, part of Post-COVID Consortium led by NFU (ZonMw funding round: Onderzoeks- en expertisenetwerk post-COVID). Collaboration with Amsterdam UMC and ErasmusMC.

December 2023: Characterization of aberrant cellular immune response in post-COVID, using innovative Signal Transduction Pathway technology (ZonMw funding round: Diagnostiek en behandeling van post-COVID). Collaboration with ErasmusMC, Rotterdam, The Netherlands.

  • DCDC-Tx founded

    DCDC Tx B.V. was founded as a wholly owned subsidiary of Koraal Tx.

  • Koraal Tx founded

    Koraal Tx B.V. was founded as the IP holding of DCDC Tx.